Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Acquisition of Kenalog®, a branded commercial injectable product
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Piramal Pharma Limited has announced the acquisition of Kenalog®, a branded commercial injectable product. The disclosure is made under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements, 2015, which mandates listed companies to inform stock exchanges about material events. Kenalog® is an established branded injectable product being added to Piramal Pharma's commercial portfolio. The financial details of the deal, such as the acquisition price, were not specified in the headline.
This acquisition expands Piramal Pharma's branded injectable product portfolio, which could positively impact revenue and market presence in the injectables segment. Shareholders should watch for further details on deal size and expected financial contributions.